Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.
Mustapha AbubakarMaeve MulloolySarah J NyanteRuth M PfeifferErin J Aiello BowlesRenata CoraClara BodelonEboneé N ButlerDonna ButcherLawrence SternbergMelissa A TroesterSheila WeinmannMark ShermanAndrew G GlassAmy Berrington de GonzálezGretchen L GierachPublished in: JNCI cancer spectrum (2022)
The findings support MBD decline as a prognostic marker of tamoxifen response among patients with aggressive ER-positive BC phenotypes, for whom understanding treatment effectiveness is critical.